About praxis precision medicines inc - PRAX
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.
PRAX At a Glance
Praxis Precision Medicines, Inc.
99 High Street
Boston, Massachusetts 02110
| Phone | 1-617-300-8460 | Revenue | 8.55M | |
| Industry | Pharmaceuticals: Major | Net Income | -182,819,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 249.53% | |
| Fiscal Year-end | 12 / 2025 | Employees | 116 | |
| View SEC Filings |
PRAX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 161.126 |
| Price to Book Ratio | 3.356 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -4.939 |
| Enterprise Value to Sales | 115.387 |
| Total Debt to Enterprise Value | 0.001 |
PRAX Efficiency
| Revenue/Employee | 73,732.759 |
| Income Per Employee | -1,576,025.862 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.03 |
PRAX Liquidity
| Current Ratio | 10.769 |
| Quick Ratio | 10.769 |
| Cash Ratio | 10.455 |
PRAX Profitability
| Gross Margin | 95.814 |
| Operating Margin | -2,340.29 |
| Pretax Margin | -2,137.484 |
| Net Margin | -2,137.484 |
| Return on Assets | -64.028 |
| Return on Equity | -70.981 |
| Return on Total Capital | -40.916 |
| Return on Invested Capital | -70.778 |
PRAX Capital Structure
| Total Debt to Total Equity | 0.307 |
| Total Debt to Total Capital | 0.306 |
| Total Debt to Total Assets | 0.283 |
| Long-Term Debt to Equity | 0.025 |
| Long-Term Debt to Total Capital | 0.025 |